Therapeutic DNA Vaccine Company Inovio Biomedical Reports First Quarter 2008 Financial Results Inovio Biomedical Corporation (INO) (Inovio) today reported financial results for the quarter ended March 31, 2008.Total revenue for the quarter ended March 31, 2008, was $653,000, compared with $504,000 for the same period in 2007.
For...
Therapeutic DNA Vaccine Company Inovio Biomedical Reports First Quarter 2008 Financial Results SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (AMEX: INO - News) (Inovio) today reported financial results for the quarter ended March 31, 2008.Total revenue for the quarter ended March 31, 2008, was $653,000, compared with ...
The Street Corner: Synta Pharmaceuticals to Host First-Quarter 2008 Conference Call on May 14, 2008 (M2 PressWIRE Via Acquire Media NewsEdge) RDATE:09052008 Streetinvesting.com has now resumed our progressive Synta Pharmaceuticals Corp.(NASDAQ:SNTA) as it fell down $0.03 on below average volume early trading Friday, May 9, 2008.
Based...
Market Review: Javelin Pharmaceuticals to Announce First Quarter 2008 Financial Results (M2 PressWIRE Via Acquire Media NewsEdge) RDATE:09052008 Streetinvesting.com has now resumed our progressive Javelin Pharmaceuticals, Inc.(NYSE:JAV) as it opened up $0.07 nearing its 52 week low of $2.31 on below average volume early...
BUYINS.NET: (SCRX) SqueezeTrigger Price is $19.582. There is $222,145,872.00 That Short Sellers Still Need To BUYINS.NET / www.squeezetrigger.com is monitoring Sciele Pharma, Inc.- Common Stock (NASDAQ:SCRX) in real time and just received an alert that is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in...
KPCB boosts clean-tech investments One of Silicon Valley's leading venture capital firms has more than tripled the amount of money it has set aside for investment in clean technology companies.The move by Kleiner Perkins Caufield & Byers, whose successful ...
Street Tips: Omrix Biopharmaceuticals Announces First Quarter 2008 Financial Results Streetinvesting.com has now resumed our progressive Omrix Biopharmaceuticals, Inc.(NASDAQ:OMRI) as it fell down $0.15 on below average volume early trading Friday, May 9, 2008.
Based on the Company's most recent news release; we will be...
The Street Corner: Market Review on Celera Group Streetinvesting.com has now resumed our progressive Celera Group (NYSE:CRA) as it fell down $0.15 on below average volume early trading Friday, May 9, 2008.Based on the Company's most recent news release; we will be progressively...
Funding philanthropy through innovation Philanthropy, most would argue, is a good thing, and to be encouraged in all guises by all mechanisms.Yet donating money to charitable causes can be far from simple, particularly for businesses, given the complex tax and legal structures...
Trimeris Reports Financial Results for the First Quarter 2008 -- Company reports earnings of $0.10 per share for the first quarter of 2008 -- Cash and investments increase to $80.0 million up from $69.6 million at December 31, 2007 -- Company announces special cash dividend and share repurchase...
GenVec, Inc. Q1 2008 Earnings Call Transcript GenVec, Inc.(GNVC) Executives Douglas Swirsky CFO Paul Fischer President and CEO Mark Thornton SVP of Product Development Analysts Debjit Chattopadhyay Boenning Ren Benjamin Rodman & Renshaw Brian McCarthy Merriman Curhan Ford...
Pfizer to Invest Heavily in Korea Pfizer, the world's biggest drugmaker, is courting Korea.Pfizer announced in June last year that it would spend a total of 300 million dollars in Korea by 2012 to develop drugs and basic technology.
Over the past year, the...
Omrix Biopharmaceuticals Inc. Earnings Call Transcript Good day ladies and gentlemen and welcome to the first quarter 2008 OMRIX Biopharmaceuticals financial results conference call.My name is Lacy and I'll be your coordinator for today.
(Operator Instructions) I would now like to turn the...
Aeolus Pharmaceuticals Announces Second Quarter Fiscal Year 2008 Financial Results - Aeolus Pharmaceuticals, Inc.(OTCBB:AOLS) announced today financial results for the three months ended March 31, 2008.
The Company reported a net loss of $697,000, or $0.02 per share, compared to a loss of $544,000, or $0.02 per share,...
Zacks Analyst Blog Highlights: ValueClick, eBay, Google, Pozen and GlaxoSmithKline CHICAGO--(BUSINESS WIRE)--Zacks.com announces the list of stocks featured in the Analyst Blog.Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.
Stocks recently...
Advent International Acquires LaborMed Pharma Advent International, a leading global buyout firm, has completed the acquisition of LaborMed Pharma from its founders.LaborMed, based in Bucharest, manufactures and distributes generic pharmaceuticals, primarily for cardiovascular and...
New Analyst Reports for GILEAD SCIENCES INC, ISIS PHARMACEUTICALS INC, CURIS INC, and MILLENNIUM PHARMACEUTICA NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Maybach.Free Analyst Review LONDON--(MARKET WIRE)--May 9, 2008 -- MaybachFinancial.com is one of the fastest growing independent and unbiased research firms in...
Reporters Barred from Ariad, Celgene, Cougar Roundtable? Pharma's Market Blog, blog, pharmaceuticals, cnbc,cnbc.com, huckman, cnbc, cnbc.com Occasionally -- when the bosses will let me -- I take a day to network, learn and maybe pick up a story idea or two by attending a biotech or healthcare ...
Con Edison Files New Energy Investment Plan With Rate Proposals for 2009 and Beyond , 9:54 AM EST Consolidated Edison Company of New York, Inc.(Con Edison) today announced that the company is filing new electric rate and investment plans with the New York State Public Service Commission (PSC) to begin April 1, 2009...
Omrix Biopharmaceuticals Announces First Quarter 2008 Financial Results NEW YORK--(BUSINESS WIRE)--Omrix Biopharmaceuticals, Inc.(Omrix or the Company) (NASDAQ: OMRI - News), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, today announced...
Osiris Therapeutics Reports First Quarter 2008 Financial Results COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc.(NASDAQ:OSIR - News), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and...
Zacks Analyst Interview Highlights: France Telecom, Total, Sanofi-Aventis, Royal Dutch Shell and BP CHICAGO--(BUSINESS WIRE)--Zacks.com releases the latest Analyst Interview.Todays interview is with senior analyst Santiago Burgaleta, who discusses France Telecom (NYSE: FTE - News), Total (NYSE: TOT - News), Sanofi-Aventis SA (NYSE: SNY ...
Omrix Biopharmaceuticals Announces First Quarter 2008 Financial Results NEW YORK--(BUSINESS WIRE)--Omrix Biopharmaceuticals, Inc.(Omrix or the Company) (NASDAQ: OMRI - News), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, today announced...
Critical Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2008 LEXINGTON, Mass.--(BUSINESS WIRE)--Critical Therapeutics, Inc.(NASDAQ: CRTX - News), a biopharmaceutical company focused on developing and commercializing innovative products for respiratory and inflammatory diseases, today reported...
Biogen Idec Commences Mailing of Proxy Materials to Shareholders CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (Nasdaq: BIIB - News) today commenced the mailing of proxy materials encouraging shareholders to vote at the companys June 19, 2008 Annual Meeting for four highly regarded and accomplished...
